Chronic obstructive pulmonary disease
Conditions
Interventions
Intervention Group:Device selection is guided by PIFr measurements. Pre-prescription on-site training is provided to evaluate inhaler competency, with daily technique verification (>= 3 times/day). Ea
Routine Care Group :The Routine Care Group received treatment and follow-up with medications prescribed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report.
Sponsors
Zhongshan hospital, Fudan University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Peri-discharge Period: Hospitalized for an acute exacerbation of COPD (AECOPD) and now in the recovery phase (peri-discharge period), meeting the 2024 GOLD guideline definitions for: COPD: Post-bronchodilator FEV1/FVC = 10. 4.Exacerbation History: At least 2 moderate exacerbations or 1 severe exacerbation in the past year. 5.Informed Consent: Ability to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Stable COPD: Patients in the stable phase of COPD (where symptoms such as cough, sputum, and shortness of breath are stable or mild, and the condition has essentially returned to the pre-exacerbation state). 2.Requirement/Contraindication for Long-Term Corticosteroid Therapy: Presence of comorbidities requiring or contraindicated for long-term corticosteroid therapy, such as asthma, interstitial lung disease, sarcoidosis, cystic fibrosis, active pulmonary tuberculosis, recurrent aspiration pneumonia, etc. 3.Severe Life-Threatening Comorbidities: Presence of severe comorbidities posing an immediate threat to life, with an expected survival of less than 1 year (e.g., severe heart disease, severe chronic liver disease, severe kidney disease, chronic cerebrovascular disease requiring prolonged bed rest, malignancy, etc.). 4.Pregnancy or Lactation: Women who are pregnant or breastfeeding. 5.Current Participation in Other Interventional Studies: Patients currently participating in any other interventional clinical trial or study. 6.Lack of Legal Capacity: Patients who lack legal capacity or whose legal capacity is limited. 7.Investigator Discretion: Any other condition that, in the judgment of the investigator, makes the patient unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment Failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinically Important Deterioration (CID);Treatment compliance;treatment Satisfaction ; | — |
Countries
China
Contacts
Public ContactJing Zhang
Zhongshan hospital, Fudan University
Outcome results
None listed